Advice
following a resubmission
icatibant acetate (Firazyr®) is accepted for use within NHS Scotland.
Indication under review: Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Icatibant treatment resulted in symptom relief in patients suffering acute abdominal, cutaneous and/or laryngeal attacks of hereditary angioedema.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of icatibant. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland.
Download detailed advice155KB (PDF)
Medicine details
- Medicine name:
- icatibant (Firazyr)
- SMC ID:
- 476/08
- Indication:
- for the treatment of symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Respiratory system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 12 March 2012